S.Amdt.2111 - To provide substantial savings in health care costs to the Federal government and consumers by fostering competition among generic pharmaceutical manufacturers and ensuring that anti-competitive "pay-for-delay" settlements between brand-name and generic pharmaceutical manufacturers do not block generic drugs from entering the market.
About This Bill
Passed
Latest Action · May 24, 2012
Amendment SA 2111, under the order of 5/23/12, not having achieved 60 votes in the affirmative, was not agreed to in Senate by Yea-Nay Vote. 28 - 67. Record Vote Number: 105.